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Three new compounds have been synthesized and completely characterized by analytical and spectro-
scopic techniques. The new bipyridine-perﬂuorinated ligand L1 and the new organometallic complex
[Ru(h5-MeCp)(PPh3)2Cl] (Ru1) crystalize in the centrosymmetric triclinic space group P1. Analysis of the
phenotypic effects induced by both organometallic complexes Ru1 and [Ru(h5-MeCp)(PPh3)(L1)]
[CF3SO3] (Ru2), on human colorectal cancer cells (SW480 and RKO) survival, showed that Ru2 has a
potent anti-proliferative activity, 4e6 times higher than cisplatin, and induce apoptosis in these cells.
Data obtained in a noncancerous cell line derived from normal colon epithelial cells (NCM460) revealed
an intrinsic selectivity of Ru2 for malignant cells at low concentrations, showing the high potential of this
compound as a selective anticancer agent.
© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
Ruthenium arene complexes have emerged in the last years as
promising alternatives to the traditional platinum-based drugs in
the frame of chemotherapy [1e4]. In general, ruthenium complexes
seem to induce less side effects than platinum drugs, having
different modes of action and being many times also active against
metastases [1e4]. Two main families of these organometallic
compounds bearing {Ru(h6-arene)} [2,5] and {Ru(h5-cyclo-
pentadienyl)} [6] scaffolds have been identiﬁed. All these organo-
metallic compounds have a piano-stool structure, where three of
the coordination sites are occupied by the (h6-arene) or the (h5-erved.cyclopentadienyl) ligands, which serve to stabilize the Ru(II) centre.
The three remaining coordination sites are occupied by several co-
ligands that are able to modulate the cytotoxicity and stability of
the compounds. The ﬁrst family comprises the ruthenium(II)-arene
RAPTA-type, [Ru(h6-arene)(PTA)X2] (PTA ¼ 1,3,5-triaza-7-
phosphaadamantane) and the RAED-type compounds, [Ru(h6-
arene)(en)Cl]þ (en ¼ ethylenediamine) [5]. Several RAPTA com-
pounds have revealed in vitro and in vivo anticancer activity and
some of them showantimetastatic potential as well [5,7]. The RAED
compounds have shown important cytotoxicity against a wide
panel of human cancer cell lines [8] and [Ru(h6-biphenyl)(en)Cl]þ
showed in vivo reduction of the MCa mammary primary carcinoma
and also on the development and growth of lung metastases [9].
Relatively to the {Ru(h5-cyclopentadienyl)} family of com-
pounds, some have been distinguished as protein kinase inhibitors
[10e12], namely for the GSK3, Pim1 and PAK1 with IC50 values of
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agents led to the synthesis of compounds incorporating water
soluble phosphane ligands [13e19] in their structure. These com-
pounds have shown moderate [18] to good [13,17e19] cytotoxicity
against several cancer cell lines. The RuCp family of complexes
bearing heteroaromatic ligands is the most extensive one
[6,20e29]. In this frame, we have selected the [RuCp(N,X)PPh3]þ
general structure (where N,X is a bidentate ligand coordinated by
two nitrogen or a nitrogen and an oxygen atom) as the most
promising scaffold in terms of cytotoxic properties and stability [6].
These compounds have showed excellent IC50 values in several
human cancer cell lines with different degrees of aggressiveness
and also resistant to cisplatin (eg.: PC3, MCF7, MDAMB231, A2780,
A2780CisR, HeLa, between others) [6]. Preliminary in vivo studies
for a compound of this family, [RuCp(N,O)PPh3]þ (N,O ¼ 2-
benzoylpyridine) [21], on nude mice bearing orthotopic triple
negative breast cancer MDAMB231, proved the potential of these
complexes by suppressing tumour growth comparatively to the
controls and by inhibiting the formation of metastases [30]. These
results undoubtedly show that further studies regarding these
compounds should be undertaken.
It is known that the incorporation of ﬂuorine in bioactive mol-
ecules improve their pharmacological properties through the
enhancement of metabolic stability, changes in their physico-
chemical properties or increasing binding afﬁnities, resulting in an
enhancement of their therapeutic efﬁcacy [31,32]. In the frame of
cancer, 5-Fluoruacil (5-FU) has recognized tumour-inhibiting ac-
tivity [33]. One of the best properties introduced by ﬂuorine relies
on the increased lipid solubility, which improves the rates of ab-
sorption and transport of drugs in vivo. Recently, compounds
bearing perﬂuorinated chains coupled to ruthenium-p-cymene
[34,35] and RAPTA derivatives such as [Ru(h6-arene)(pta)(PR3)Cl]
BF4 (arene ¼ p-cymene or 4-phenyl-2-butanol;
PR3 ¼ perﬂuorinated phosphanes) [36] showed considerable anti-
proliferative activity and some of them were found to be ther-
moresponsive towards cancer cells. [(h6-C10H14)RuCl(MFPdpm or
PFPdpm)] and [(h6-C12H18)Ru-Cl (MFPdpm or PFPdpm)]
(MFPdpm ¼ 5-(4-ﬂuoro)phenyldipyrromethene; PFPdpm ¼ 5-
(penta-ﬂuoro)phenyldipyrromethene) compounds also exhibited
good cytotoxicity towards human lung cancer cell line (A549) [37].
Taking these results into consideration we report here for the ﬁrst
time the synthesis of a bipyridine bearing two perﬂuorinated
chains and the synthesis of the corresponding ruthenium-(h5-
MeCp) complex. As far as we know these compounds are unex-
plored in the frame of anticancer agents.
2. Experimental section
2.1. General procedures
All reactions andmanipulations were performed under nitrogen
atmosphere using Schlenk techniques. All solvents used were dried
and freshly distilled under nitrogen prior to use, using standard
methods [38]. 1H, 13C, 19F and 31P NMR spectra were recorded on a
Bruker Avance 400 spectrometer at probe temperature using
commercially available deuterated solvents. 1H and 13C chemical
shifts (s ¼ singlet; d ¼ duplet; t ¼ triplet; m ¼ multiplet;
comp ¼ complex) are reported in parts per million (ppm) down-
ﬁeld from internal standard Me4Si. 19F and 31P NMR spectra are
reported in ppm downﬁeld from external standard CFCl3 and 85%
H3PO4, respectively. Coupling constants are reported in Hz. All as-
signments were attributed using DEPT-135, COSY, HMBC and
HMQCNMR techniques. Infrared spectra were recorded on KBr
pellets using a Mattson Satellite FT-IR spectrophotometer. Only
considered relevant bands were cited in the text. Electronic spectrawere obtained at room temperature on a Jasco V-560 spectrometer
from solutions of 104-106 M in quartz cuvettes (1 cm optical
path). Elemental analyses were performed at Laboratorio de
Analises, at Instituto Superior Tecnico, using a Fisons Instruments
EA1 108 system. Data acquisition, integration and handling were
performed using a PC with the software package EAGER-200 (Carlo
Erba Instruments).
2.2. Synthesis
2.2.1. perFluor-bpy (L1)
The ligand synthesis was carried out by following the literature
procedure [39] with slight modiﬁcations using 4,40-dihydroxy-2,20-
bipyridine as starting material instead of 40-hydroxy-2,2:60,2-ter-
pyridine. A mixture of 4,40-dihydroxy-2,20-bipyridine (95 mg,
0.5 mmol), K2CO3 (207 mg, 1.5 mmol), a catalytic amount of 18-
crown-6 in 30 mL of acetone was stirred at room temperature for
1 h. After that, 1H,1H,2H,2H,3H,3H-Perﬂuoroundecyl iodide (589 mg,
1 mmol) dissolved in 5 mL of acetone was added dropwise to the
reaction mixture at room temperature. The reaction mixture was
reﬂuxed for 2 days. After the reaction time, the reaction mixture
was cooled to room temperature and white crystalline product was
ﬁltered and washed with an excess amount of water and acetone
and dried under vacuum.
Yield: 67%. White ﬂaky product. Mp: 150.5e153.2 C. 1H NMR
(CDCl3, Me4Si, d/ppm): 8.38 (d, 2H, JHH ¼ 5.6, H5), 7.84 (d, 2H,
JHH ¼ 2.5, H8), 6.88 (dd, 2H, J ¼ 5.6, 2.5, H6), 4.36 (t, 4H, JHH ¼ 5.9,
H10), 2.51 (m, 4H, H12), 2.35 (m, 4H, H11). 1H NMR (CDCl3 þ 2 drops
of HFIP, Me4Si, d/ppm): 8.39 (d, 2H, JHH ¼ 5.9, H5), 7.62 (d, 2H,
JHH ¼ 2.4, H8), 6.95 (dd, 2H, J ¼ 5.9, 2.5, H6), 4.22 (t, 4H, JHH ¼ 5.9,
H10), 2.39e2.25 (m, 4H, H12), 2.21e2.15 (m, 4H, H11). 1H NMR
((CD3)2CO,Me4Si, d/ppm): 8.50 (d, 2H, JHH¼ 5.1, H5), 8.08 (s, 2H, H8),
7.03e7.00 (m, 2H, H6), 4.40e4.04 (m, 4H, H10), 2.56 (m, 4H, H12). 13C
NMR [CDCl3 þ 2 drops of HFIP, d/ppm]: 166.61, 157.11, 150.00,
125.97, 123.16, 120.33, 117.52, 111.64, 109.12, 67.03, 29.87, 27.87,
20.44. 19F NMR [CDCl3 þ 2 drops of HFIP, d/
ppm]: 58.83, 92.31, 99.71, 99.92, 100.12, 101.42, 104.11.
FTIR [KBr, cm1]: 3080e2889 (yC-H aromatic), 1458 (yC-C aromatic),
1334 (yCF stretch). ESI-TOF Mass: Calcd. for C32H19F34N2O2
[MþH]þ ¼ 1109.0898, found ¼ 1109.0870. Elemental analysis (%)
calc. for C32H18F34N2O2 (1108.44): C, 34.7; H, 1.6, N, 2.5. Found: C,
34.4; H, 2.0; N, 2.3.
2.2.2. [Ru(h5-MeCp)(PPh3)2Cl] (Ru1)
The synthesis of Ru1was adapted from Ref. [40]. To a stirred and
degassed solution of hydrated ruthenium trichloride (0.5 g,
2.4 mmol) in ethanol (50 mL) was added triphenylphosphane
(2.89 g, 11 mmol) and freshly distilled methylcyclopentadiene
(5e6 mL). The dark brown mixture obtained was reﬂuxed with
vigorously stirring for 8 h until no more precipitation of the orange
complex is observed. After reﬂuxing, the mixture was cooled to
room temperature overnight. The precipitate was ﬁltered, washed
with water (2  20 mL), cold ethanol (2  20 mL) and a mixture of
ethanol and light petroleum ether (50:50 (%v/v), 2  20 mL). The
orange powder obtained was dried under vacuum originating Ru1
in moderate yield. Single crystals were isolated by recrystallization
from dichloromethane/n-hexane.
Yield: 48%; orange powder, recrystallized from dichloro-
methane/n-hexane. Mp: ca. 145 C decomposition. 1H NMR [CDCl3,
Me4Si, d/ppm]: 7.37 (t, 12H, JHH ¼ 8.2, Hmeta,PPh3), 7.21 (t, 6H,
JHH ¼ 7.2, Hpara,PPh3), 7.11 (t, 12H, JHH ¼ 7.4, Hortho,PPh3), 3.96 (s, 2H,
H3), 3.26 (s, 2H, H4), 1.92 (s, 3H, H1). 13C NMR [CDCl3, d/ppm]: 138.73
(Cq, PPh3), 133.94 (CH, PPh3), 128.68 (CH, PPh3), 127.50 (CH, PPh3),
104.93 (C2), 80.95 (C3), 76.69 (C4), 12.03 (C1). 31P NMR [CDCl3, d/
ppm]: 40.11 [s, PPh3]. FTIR [KBr, cm1]: 2920-2852 cm1 (yC-H
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(Sh), 386 (Sh), 448 (Sh). UVevis [CH2Cl2, lmax/nm (ε/M1cm1)]:
289 (Sh), 361 (2394), 450 (Sh). Elemental analysis (%) calc. for
C42H37ClP2Ru (740.21): C, 68.1; H, 5.0. Found: C, 67.8; H, 5.0.
2.2.3. [Ru(h5-MeCp)(L1)(PPh3)][CF3SO3] (Ru2)
L1 (0.300 g, 0.3 mmol) and AgCF3SO3 (0.094 g, 0,4 mmol) were
added to a stirred solution of Ru(h5-MeCp)(PPh3)2Cl] (0.262 g,
0,4 mmol) in dichloromethane (40 mL). After reﬂuxing for 4 h the
solution turned from orange to brown. AgCl and PPh3 precipitate
were eliminated from the solution by cannula ﬁltration and the
solvent removed by vacuum. Forced precipitations from dichloro-
methane/n-hexane mixture allowed the isolation of the pure
complex (Ru2).
Yield: 31%; brown powder, precipitated from dichloromethane/
n-hexane. Mp: ca. 90.4 C decomposition. 1H NMR [(CD3)2CO,
Me4Si, d/ppm]: 9.16 (d, 2H, JHH ¼ 8, H5), 7.82 (d, 2H, JHH ¼ 2.4, H8),
7.41 (t, 3H, JHH ¼ 8, Hpara,PPh3), 7.33 (t, 6H, JHH ¼ 8, Horto,PPh3), 7.14
(t, 6H, JHH ¼ 8 Hmeta,PPh3), 7.02 (dd, 2H, JHH ¼ 6.5, 2.6, H6), 4.63 (s,
2H, H4), 4.51 (m, 2H, H3), 4.39 (m, 4H, H10), 2.47 (m, 4H, H12), 2.15
(m, 4H, H11) 1.66 (s, 3H, H1). 13C NMR [(CD3)2CO, d/ppm]: 166.25
(C7), 158.07 (C9), 157.22 (C5), 133.90 and 129.29 (d, JCP ¼ 11.2; d,
JCP ¼ 9.5, CH-PPh3), 133.36 (d, 1JCP ¼ 40.4, Cq- PPh3), 130.69 (d,
4JCP ¼ 1.8, CH-PPh3), 114.26 (C6), 110.23 (C8), 102.53 (C2), 76.00 (C4),
75.80 (C3), 68.63 (C10), 28.03 (C12), 20.85 (C11), 11.83 (C1),
133.56 þ 133.16þ123.91 þ 120.71 (C13-C20). 31P NMR [(CD3)2CO, d/
ppm]: 51.50 [s, PPh3]. 19F NMR [(CD3)2CO, d/
ppm]: 78.83, 81.65, 114.77, 122.24/-
122,44, 123.27, 123.93, 126.73. FTIR [KBr, cm1]: 3078e2893
(yC-H aromatic), 1250 (yCF3SO3 counter ion), 1342 (yCF stretch).
UVevis [DMSO, lmax/nm (ε/M1cm1)]: 274 (27136), 293 (Sh), 345
(Sh), 420 (4628), 475 (Sh). UVevis [CH2Cl2, lmax/nm (ε/M1cm1)]:
271 (23211), 292 (Sh), 342 (Sh), 419 (4100), 473 (Sh). Elemental anal.
(%) Calc. for C57H40F37N2O5PRuS$½C6H14: C, 41.3; H, 2.7; N, 1.6; S,
1.8. Found: C, 41.3; H, 2.5; N, 1.2; S, 2.0.
2.3. X-ray crystal structure determination
The crystal of L1 was immersed in cryo-oil, mounted in a
MiTeGen loop, and measured at 123 K on a Rigaku Oxford Diffrac-
tion Supernova using Cu Ka (l ¼ 1.54184 Å) radiation. The CrysA-
lisPro [41] program package was used for cell reﬁnement and data
reduction. A Gaussian absorption correction (CrysAlisPro [41]) was
applied to the intensities before structure solution. The structure
was solved by charge ﬂipping method using the SUPERFLIP [42]
software. Structural reﬁnement was carried out using SHELXL-
2015 [43]. All H-atoms were positioned geometrically and con-
strained to ride on their parent atoms, with C-H ¼ 0.93e0.97 Å and
Uiso ¼ 1.2,Ueq (parent atom).
Three-dimensional X-ray data for [RuCl(MeCp)(PPh3)2]$CH2Cl2
(Ru1) were collected on a Bruker SMART Apex CCD diffractometer
at 100(2) K, using a graphite monochromator and Mo-Ka radiation
(l¼ 0.71073 Å) by the f-u scanmethod. Reﬂections weremeasured
from a hemisphere of data collected of frames each covering 0.3 in
u. A total of 76661 reﬂections were measured, all of which were
corrected for Lorentz and polarization effects and for absorption by
semi-empirical methods based on symmetry-equivalent and
repeated reﬂections. Of the total, 6873 independent reﬂections
exceeded the signiﬁcance level jFj/s(jFj) > 4.0. After data collection,
in each case a multi-scan absorption correction (SADABS) [44] was
applied, and the structure was solved by direct methods and
reﬁned by full matrix least-squares on F2 data using SHELX suite of
programs [45]. The structure was solved by direct methods and
reﬁned by full-matrix least-squares methods on F2. The non-
hydrogen atoms were reﬁned with anisotropic thermalparameters in all cases. Hydrogen atoms were included in calcu-
lation positions and reﬁned in the riding mode. A ﬁnal difference
Fourier map showed a residual density outside next to the chlorine
atom of solvent molecule, which was not reﬁned: 1.406 and0.710
e.Å3. A weighting scheme w ¼ 1/
[s2(Fo2) þ (0.047100 P)2 þ 1.180300 P] for Ru1, where P ¼
(jFoj2 þ 2jFcj2)/3, was used in the latter stages of reﬁnement. CCDC
No. 1535674 and 1493775 contain the supplementary crystallo-
graphic data for Ru1 and L1, respectively. These data can be ob-
tained free of charge via http://www.ccdc.cam.ac.uk/conts/
retrieving.html, or from the Cambridge Crystallographic Data
Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (þ44) 1223-
336-033; or e-mail: deposit@ccdc.cam.ac.uk. Crystal data and de-
tails of the data collection and reﬁnement for the new compounds
were collected in Table 1.2.4. Electrochemical experiments
The cyclic voltammograms were obtained at room temperature
using a EG&G Princeton Applied Research Potentiostat/Galvanostat
Model 273A equipped with Electrochemical PowerSuite v2.51
software for electrochemical analysis, in anhydrous acetonitrile or
dichloromethane with tetrabutylammonium hexaﬂuorophosphate
(0.1 and 0.2 M) as supporting electrolyte. The electrochemical cell
was a homemade three electrode conﬁguration cell with a
platinum-disc working electrode (1.0 mm) probed by a Luggin
capillary connected to a silver-wire pseudo-reference electrode and
a platinum wire auxiliary electrode. All the potentials reported
were measured against the ferrocene/ferrocenium redox couple as
internal standard and normally quoted relative to SCE (using the
ferrocenium/ferrocene redox couple E1/2 ¼ 0.46 or 0.40 V versus
SCE for dichloromethane or acetonitrile, respectively). All the ex-
periments were performed in nitrogen atmosphere. Both the
sample and the electrolyte (Fluka) were dried under vacuum for
several hours prior to the experiment. Reagent grade solvents were
dried, puriﬁed by standard procedures and distilled under nitrogen
atmosphere before use.2.5. Stability studies in DMSO and DMSO/DMEM
For the stability studies, all the complexes were dissolved in
DMSO or 2% DMSO/98% DMEM at ca. 1  104 M for Ru1 and
8  105 M for Ru2 and their electronic spectra were recorded in
the range allowed by the solvents at set time intervals.2.6. Partition coefﬁcient determination
The lipophilicity of Ru1 and Ru2 was measured by the shake-
ﬂask method [46]. The n-octanol and the aqueous phases were
mutually saturated before the experiments, using analytical grade
octanol and double distilled water. The samples were dissolved in
octanol (stock solution: 1.15 104 M for Ru1 and 1.03 104 M for
Ru2) and aliquots of the stock solution were equilibrated with
water for 4 h in amechanical shaker. The phase ratiowas 2mL/2mL
(n-octanol/water). After separation of the equilibrated phases (by
centrifugation at 5000 rpm for 10 min) the concentration decrease
of the solute was determined in the n-octanol phase by UVeVis
spectrophotometry at the lmax of each compound (355 nm for Ru1
and 419 nm for Ru2). Triplicate experiments have been performed
for each complex. The concentration for each sample was deter-
mined using the calibration curve. The partition coefﬁcients of Ru1
and Ru2 were calculated using the equation:
log o=w
¼ log

½complexo
½complexw

Table 1
Crystal data and structure reﬁnement for L1 and [Ru(MeCp)(PPh3)2Cl]$CH2Cl2 (Ru1).
Ru1 L1
CCDC No. 1535674 1493775
Formula C43H39Cl3P2Ru C32H18F34N2O2
Formula weight 825.10 1108.48
T, K 100(2) 123(1)
Wavelength, Å 0.71073 1.54184
Crystal system Triclinic Triclinic
Space group P1 P1
a/Å 9.7702(4) 5.3931(5)
b/Å 14.1031(5) 7.6334(8)
c/Å 14.9277(5) 24.663(3)
a/º 73.247(2) 92.674(9)
b/º 72.323(2) 94.043(8)
g/º 78.853(2) 110.404(9)
V/Å3 1863.93(12) 946.50(17)
Z 2 1
F000 844 546
Dcalc/g cm3 1.470 1.945
m/mm1 0.752 2.195
q/(º) 1.48 to 26.42 6.604e64.495
Rint 0.0535 0.0768
Crystal size/mm3 0.30  0.21  0.18 0.14  0.06  0.04
Goodness-of-ﬁt on F2 1.124 1.030
R1a 0.0301 0.0860
wR2 (all data)b 0.0896 0.2229
Largest differences peak and hole
(eÅ3)
1.406 and 0.710 0.503 and 0.543
a R1 ¼ SrjFoj - jFcjr/SrFor.
b wR2 ¼ {S[w(rjFoj2 -jFcj2r)2]r/S[w(Fo2)2]}1/2.
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The noncancerous NCM460 cell line derived from normal colon
epithelial mucosa, was obtained from INCELL's [47], and the two
colorectal cancer (CRC) derived cell lines, SW480 and RKO, were
obtained from American Type Culture Collection (ATCC). All cell
lines were maintained at 37 C under a humidiﬁed atmosphere
containing 5% CO2. NCM460 and SW480 cells were grown in RPMI
medium and RKO cells in DMEM, both supplemented with 10% FBS
and 1% penicillin/streptomycin. Cells were subcultured once aweek
when 80% of conﬂuence was reached and then seeded in sterile test
plates for the assays.
2.8. Compounds dilution and storage
The Ru1 and Ru2 compounds were dissolved in DMSO. Aliquots
were prepared and stored at 20 C, protected from light, and
discharged after one month, by which time new samples were
prepared.
2.9. Sulphorhodamine B (SRB) assay
RKO, SW480 and NMC460 cells were seeded at a concentration
of 4  104 cells/ml, 1  105 cells/ml and 3  105 cells/ml respec-
tively, in 24-well test plates. After 24 h of seeding, cells were
incubated with different concentrations of the Ru1 and Ru2 com-
pounds during 48 h. For each cell line and compound, we per-
formed two negative controls, a control (1) in which cells were
incubated only with growthmedium and another DMSO control (2)
in which the cells were exposed to the concentration of DMSO in
which the highest concentration of the compound was dissolved
(maximum of 0.1% of DMSO per well (v/v)), to discard any inﬂuence
of the DMSO in the results. After 48 h of treatment, cells were ﬁxed
in ice-cold methanol containing 1% acetic acid for at least
90 min at 20 C. Fixing solution was then removed and the plate
was left air-dry at room temperature, then the ﬁxed cells wereincubatedwith 0.5% (w/v) SRB dissolved in 1% acetic acid for 90min
at 37 C protected from light. After washing with 1% acetic acid and
air-drying at room temperature, SRB was solubilized with 10 mM
Tris pH10. Absorbance was read at 540 nm in a microplate reader
(SpectraMax 340PC Molecular Devices). Results were expressed
relatively to the negative control 1, which was considered as 100%
of cell growth. The results were obtained from at least three in-
dependent experiments, each experiment was done in triplicate.
The statistical analysis performed using one-way ANOVA test and
the IC50 were estimated using GraphPad Prism 6 software.
2.10. Colony formation assay
SW480 and RKO cell lines were seeded, at a concentration of
500 cells/ml and 300 cells/ml, respectively, in 6-well plates. After
24 h of seeding, cells were treated with ¼ IC50 and IC50 values of
Ru2 and incubated for 48 h, when cells were washed with PBS and
the mediumwas replaced with fresh medium. The negative control
cells were treated with DMSO 0.1%. 5 days later, cells were washed
with PBS and ﬁxatedwith glutaraldehyde 6% (v/v) and crystal violet
0.5% (w/v) for three hours. Then, cells were washed with fresh
water and the plate was left air dry. Colonies were counted using
ImageJ 1.50i software. The results represent mean ± S.D. of at least
three independent experiments. Statistical analysis was performed
by one-way ANOVA with Turkey's multiple comparisons test.
*P  0.05; **P  0.01; ***P  0.001 compared with negative control.
2.11. TUNEL assay
The cell lines SW480 and RKOwere seeded, in 6-well plates, at a
concentration of 2  105 cells/ml and 8  104 cells/ml, respectively.
24 h after seeding, cells were exposed to the IC50 and 2 IC50 values
of Ru2. The negative control cells were treated with DMSO 0.1%.
After 48 h, both ﬂoating and attached cells were collected and
washed with PBS. To the resuspended pellet was added para-
formaldehyde 4%, for 15 min at room temperature (RT), to ﬁx the
cells, whichwere thenwashedwith PBS. Cytospins were performed
using Cytospin 4 Cytocentrifuge (Thermo Fisher Scientiﬁc). Cells
were then washed in PBS and permeabilized with ice-cold 0.1%
Triton X-100 in 0.1% sodium citrate. TUNEL was performed using In
Situ Cell Death Detection Kit, Fluorescein (Roche, Mannheim, Ger-
many). Slides were mounted on Vectashield Mounting Medium
with DAPI and maintained at 20 C until visualization in a ﬂuo-
rescence microscope (Leica DM 5000B, Leica Microsystems, Wet-
zlar, Germany). Values represent mean ± S.D. of at least three
independent experiments. Statistical analysis was performed by
one-way ANOVA with Turkey's multiple comparisons test.
*P  0.05; **P  0.01; ***P  0.001; ****P  0.0001 compared with
negative control.
2.12. Cell cycle analysis
RKO and SW480 cell lines were seeded at a concentration of
8  104 cells/ml and 2  105 cells/ml, respectively, in 6-well plates.
After 24 h, cells were treated with the IC50 and 2  IC50 values of
Ru2. The negative control cells were treated with DMSO 0.1%. 48 h
later, both dead and live cells were collected, washed with PBS and
ﬁxed and permeabilized with 70% cold ethanol for 15min. Then the
cells were washed with PBS and incubated with RNase A (200 mg/
mL) for 15 min at 37 C and with propidium iodide (0.5 mg/mL) for
30 min, protected from the light, at RT before analysis on a ﬂow
cytometer. To analyze the data and quantify the amount of cells in
each cell-cycle phase was used FlowJo 7.6 software. Values repre-
sent mean ± S.D. of at least three independent experiments. Sta-
tistical analysis was performed by multiple t-tests. . *P  0.05
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Selected 1H NMR data in CDCl3 or (CD3)2CO for compounds L1, Ru1 and Ru2.
Compound MeCp (ppm) Bipyridine (ppm)
H1 H3 H4 H5 H6 H8 H10 H11 H12
Ru1a 1.92 3.96 3.26 _ _ _ _ _ _
L1a _ _ _ 8.38 6.88 7.84 4.36 2.35 2.51
L1b 8.50 7.03e7.00 8.08 4.40e4.04 * 2.56
Ru2b 1.66 4.51 4.63 9.16 7.03 7.82 4.39 2.15 2.47
*under the solvent signal.
a In CDCl3.
b In (CD3)2CO.
Fig. 1. UVevisible spectrum in CH2Cl2 for complexes Ru1 (- - - -) and Ru2 (¡¡¡).3. Results and discussion
3.1. Synthesis
Two new ruthenium(II) organometallic compounds have been
synthesized. The new [Ru(h5-MeCp)(PPh3)2Cl] (Ru1) precursor was
synthesized by addition of freshly distilled methylcyclopentadiene
and triphenylphosphane to a stirred ethanolic solution of ruthe-
nium trichloride, following a modiﬁed literature procedure [40]
giving dark orange crystals in 48% yield. As for the new cationic
complex [Ru(h5-MeCp)(PPh3)(L1)]þ Ru2, the synthesis was per-
formed in reﬂux in dichloromethane for 4 h, by s coordination of
bidentate N,N per-ﬂuorinated chelating ligand L1 to Ru1, in the
presence of silver triﬂate (Scheme 1). Isolation of Ru2 as a brown
powder was achieved in 31% yield. The perﬂuorinated bipyridyl
ligand L1 was obtained by following a modiﬁed literature proced-
ure [39] reacting 4,40-dihydroxy-2,20-bipyridine with C8F17-C3H6I
perﬂuorinated alkyl iodide in acetone in the presence of potassium
carbonate (K2CO3).
The formulation and purity of all the new compounds (L1, Ru1
and Ru2) is supported by analytical data, FT-IR spectroscopy, 1H,
13C, 31P and 19F NMR spectroscopic data and elemental analyses. In
the case of L1 and Ru1, X-ray diffraction of single crystals was also
possible (see below).
The solid state FT-IR spectra (KBr pellets) of the complexes Ru1
and Ru2 present the characteristic band for the methyl-
cyclopentadienyl ring along with the phenyl aromatic rings of the
bipyridine (3100-2850 cm1; also present in L1). Additional bands
attributed to the carbon-carbon and carbon-ﬂuorine vibrations
were also found in the range of 1220e1250 cm1, for compounds L1
and Ru2. The presence of the counter-ion CF3SO3 (~1250 cm1) in
the solid state IR spectra conﬁrms the proposed cationic nature of
complex Ru2.
The 1H NMR spectrum (in CDCl3) of L1 shows three signals at the
aromatic region (d¼ 8.38, 7.84 and 6.88 ppm)which arises from the
three chemically non-equivalent aromatic protons of the bipyridine
moiety. The CH2 hydrogens of perﬂuorinated alkyl chain which is
directly attached to the oxygen atom are observed as a triplet at
4.36 ppm and other two consecutive CH2 hydrogens appeared as
multiplets at 2.51 and 2.35 ppm, respectively. The 13C NMRof ligand
was also obtained in CDCl3 by adding 2e3 drops of hexaﬂuoro
isopropanol (HFIP) to increase the solubility of the ligand and
spectral data are presented in experimental section.
The 1H NMR spectra of Ru1 shows the expected signals of (h5-
MeCp) moiety at 3.96 and 3.26 ppm, corresponding to the non-
equivalent protons on the Cp ring. These signals are more shiel-
ded than in the related [RuCp(PPh3)2Cl] compound (d¼ 4.12 ppm in
CDCl3), showing the presence of the donating methyl group on the
Cp ring. Evidence of the coordination of L1 to the ruthenium centreScheme 1. Synthetic route of the new Ru(II) complex [Ru(h5-MeCp)(PPh3in Ru2 can be observed by the deshielding on the H5 protons,
adjacent to the nitrogen of the bipyridine ring, and a shielding on
the H8 protons ligand (Table 2). This effect has been already
observed for related compounds, where the bipyridine is
substituted at the para-position (relatively to the nitrogen) [26].
The displacement of the h5-coordinated MeCp ring signals
(d¼ 4.63, 4.51 ppm) also conﬁrms that the synthesis was successful
and coherent with a cationic compound. The 13C NMR spectra
shows the same general effect observed for the protons in both
complexes. A unique sharp singlet resonance corresponding to the
coordinated triphenilphosphane co-ligand was found in the 31P
NMR (d 40.1 Ru1, d 50.5 Ru2).3.2. UVevisible (UVeVis) studies
3.2.1. Compounds characterization
The electronic absorption spectra of all compounds was per-
formed in 1  104 to 1  106 M solutions of dichloromethane
and/or dimethylsulfoxide. Spectra of compounds Ru1 and Ru2
present an intense absorption band at ca. 260 nm that can be
attributed to the organometallic fragment {Ru(h5-MeCp)(PPh3)}þ.)(L1)][CF3SO3]; all compounds are numbered for NMR assignments.
Fig. 2. Molecular structure (top) and packing (bottom) of L1. Thermal ellipsoids are drawn at 50% probability level.
R.G. Teixeira et al. / European Journal of Medicinal Chemistry 143 (2018) 503e514508In the case of Ru2 another intense band at 290 nm from the pep*
electronic transitions occurring in the aromatic ring of L1 is
observed. In the visible range, Ru2 presents an absorption band and
a shoulder at 419 nm and ~470 nm, respectively, that can be
attributed to charge transfer transitions between the N,N-bidentate
ligand L1 and the ruthenium centre (Fig. 1) as observed in related
complexes [19,22,25]. No signiﬁcant modiﬁcations on band posi-
tioning were noticed in both solvents.
3.2.2. Complexes stability in aqueous solutions and estimation of
lipophilicity
Envisaging the use of these new compounds as cytotoxic agents
and their study in human cancer cell lines, their stability and
behaviour in aqueous solution was studied in DMSO and in culture
cellular media, using 2% DMSO, by UVeVis spectroscopy. DMSO is
the co-solvent used in the biological assays in order to allow
complete solubilization of the compounds. Ru1 spectral changesFig. 3. ORTEP plot for the complex [Ru(MeCp)(PPh3)2Cl] (Ru1). All the non-hydrogen
atoms are presented by their 50% probability ellipsoids. Hydrogen atoms are omitted
for clarity.were about 25 and 10% at 24 h in DMSO and DMSO/DMEM,
respectively, probably due to hydrolysis of the Ru-Cl bond (Fig. S1).
Ru2 was found to be very stable with spectral changes lower than
6% over 24 h in both solutions (Fig. S2).
The importance of hydrophobicity/lipophilicity of the com-
pounds for medicinal purposes is a key feature in the development
of new drugs since it affects their tissue permeability, binding to
biomolecules, between others. In this frame, the n-octanol/water
partition coefﬁcient was measured using the shake-ﬂask method,Fig. 4. Two enantiomers of the complex [Ru(MeCp)(PPh3)2Cl] (Ru1) present in the
racemic crystal packing. View through the Ru-Cl edge. Drawing was done with Mer-
cury 2.3 program in balls and sticks.
Fig. 5. Cyclic voltammogram of complex Ru2 in acetonitrile, at 100 mV/s, showing the
reversibility of the isolated oxidative process (dashed line).
Table 3
Electrochemical data for complexes Ru1 and Ru2 (all values vs. SCE, v ¼ 100 mV.s1).
Epa
(V)
Epc
(V)
E1/2
(V)
Epa e Epc (mV) Ipc/Ipa
Dichloromethane
[Ru(h5-MeCp)(PPh3)2Cl] (Ru1) 1.67 ____ ____ ____ ____
1.41 ____ ____ ____ ____
0.51 0.43 0.47 80 1.0
[Ru(h5-MeCp)(PPh3)(L1)][CF3SO3] (Ru2) 0.90 0.81 0.85 90 1.0
[RuCp(PPh3)(2,20-bipy)][CF3SO3] [25] 1.70 ____ ____ ____ ____
1.53 ____ ____ ____ ____
1.10 1.01 1.05 90 0.9
Acetonitrile
[Ru(h5-MeCp)(PPh3)2Cl] (Ru1) 0.54 0.46 0.50 80 1.0
[Ru(h5-MeCp)(PPh3)(L1)][CF3SO3] (Ru2) 0.87 0.79 0.83 80 1.0
1.59 ____ ____ ____ ____
[RuCp(PPh3)(2,20-bipy)][CF3SO3] [25] 0.92 0.84 0.88 80 0.75
Fig. 6. Effects of Ru2 compounds on cell growth of NCM460 normal colon epithelial mucosa derived cell line and RKO and SW480 colorectal cancer derived cell lines, determined by
SRB assay. The percentage of cell growth relatively to the negative control was determined after a period of 48 h of exposure to the compounds and is expressed as a mean ± SD for
each treatment from at least three independent experiments. Statistical analyzes was performed by one-way ANOVA comparing all conditions with negative control. The results
were statistically signiﬁcant with values of p < 0.0001 (****) (n ¼ 3).
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Ru1 due to the spectral changes caused by the hydrolysis of the Ru-
Cl bond, however, analysis of the spectra in octanol showed that it
has a lipophilic character, since all the compound remained in this
fraction. Ru2 is also lipophilic (logPo/w ¼ 0.25; calibration curve in
Fig. S3), as predictable by the known lipid solubility introduced by
ﬂuorine atoms.
3.3. Single crystal structure of L1 and [Ru(h5-
MeCp)(PPh3)2Cl]·CH2Cl2 Ru1
Single crystals of L1 were obtained by slow evaporation of
chloroform at room temperature. Upon X-ray diffraction, it was
revealed that the crystal of L1 belongs to the centrosymmetricTable 4
IC50 values determined by SRB assay after 48 h of incubation with Ru2 and cisplatin
in NCM460, RKO and SW480 cell lines. Values represent mean ± SD of at least three
independent experiments.
Ru2
(mM)
Cisplatin
(mM)
NCM460 8.7 ± 0.9 e
RKO 2.0 ± 0.2 12.5 ± 1.2
SW480 1.5 ± 0.3 7.0 ± 0.1triclinic space group P1. The asymmetric unit contains only half of
the ligandmolecule. The crystal packing shows intermolecular F/F
(2.799e2.871 Å) interactions along with weak aliphatic CH/N
(2.662 Å) hydrogen bonds (Fig. 2). Table S1 contains selected bond
lengths and angles for compound L1.
[Ru(MeCp)(PPh3)2Cl]$CH2Cl2 Ru1 crystallizes from dichloro-
methane solution as red blocks (crystal dimensions
0.30  0.21  0.18 mm). Fig. 3 shows an ORTEP representation of
[Ru(MeCp)(PPh3)2Cl] Ru1. The asymmetric unit contains for Ru1
one ruthenium complex and one CH2Cl2 molecule. In the molecular
structure, the ruthenium centre adopts a “piano stool” distribution
formed by the ruthenium-MeCp unit bound to two phosphane li-
gands. One chloride ion occupies the other coordination position.
X-ray structure analysis of Ru1 shows two enantiomers of the
complex [Ru(MeCp)(PPh3)2Cl] (Ru1) in the racemic crystal (space
group P1), the chirality being due to a twist of the PPh3 and Cp
units. The complex [Ru(MeCp)(PPh3)2Cl] (Ru1) presents a mirror
plane which contain Cl, Ru and the centroid of Cp ring (see Fig. 4)
[22,48]. The distances for Ru-P bond are Ru(1)-P(1) ¼ 2.3132(6) Å
and Ru(1)-P(2) ¼ 2.3204(6) Å. The distance between Ru and the
centroid of the p-bonded cyclopentadienyl moiety is 1.842(30) Å to
Ru centre (ring slippage 0.079 Å). The mean value of the Ru-C bond
distance is 2.2048(2) Å. Table S2 contains selected bond lengths and
angles for compound Ru1.
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The redox behaviour of complex [Ru(h5-MeCp)(PPh3)(L1)]
[CF3SO3] (Ru2) and the precursor [Ru(h5-MeCp)(PPh3)2Cl] (Ru1)
was studied by cyclic voltammetry in dichloromethane and
acetonitrile solutions, containing ammonium hexaﬂuorophosphate
as supporting electrolyte, between the limits imposed by the sol-
vents (Table 2).
Complex Ru1 showed to be redox-active in both solvents, with
ruthenium centered processes (oxidation) at 0.54 V (ACN) and
0.51 V (DCM) with ipc/ipa ratios of 0.7, suggesting some instability of
the oxidized ruthenium species at the electrode surface. However,
when the scan direction is immediately reverted after the oxidationFig. 7. Colony formation assay of RKO and SW480 cell lines after exposure with Ru2. (A)
and SW480 cell lines. Values represent mean ± S.D. of at least three independent experim
comparisons test. *P ¼ 0.05; **P ¼ 0.01; ***P ¼ 0.001 compared with negative control. (B)potential, the processes became quasi-reversible (E1/2 ¼ 0.50 V and
E1/2 ¼ 0.47 V for acetonitrile and dichloromethane, respectively). In
dichloromethane, this ruthenium centered process is followed by
two other irreversible oxidative processes, also found in similar
compounds [25], and probably originated by the oxidation of spe-
cies resulting of the ﬁrst RuII/RuIII oxidation process.
In a 0.1 M [n-Bu4N][PF6]/acetonitrile solution (Fig. 5), complex
Ru2 was characterized by a quasi-reversible ruthenium centered
process at E1/2 ¼ 0.83 V and an irreversible reduction at
Epc ¼ 1.69 V, which can be attributed to a ligand-based process.
The electrochemical response of Ru2 in dichloromethane is
consistent with the behaviour observed in acetonitrile, with a
quasi-reversible redox process at E1/2 ¼ 0.855 V, found when theAnalysis of the clonogenic ability, after 48 h of incubation with ¼ IC50 and IC50, in RKO
ents. Statistical analysis was performed by one-way ANOVA with Turkey's multiple
Representative images of colony formation assay in RKO and SW480 cell lines.
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uted to the Ru(II)/Ru(III) redox couple.
The oxidation potential found for the Ru(II)/Ru(III) redox pair is
lower than the one found for the related [Ru(h5-C5H5)(PPh3)(2,20-
bpy)][CF3SO3] complex (E1/2 ¼ 1.05 V) [25] in the same experi-
mental conditions (Table 3), indicating that the substitution of the
cyclopentadienyl ring by the electron donor methyl group in-
ﬂuences the electronic capability of the ruthenium(II) centre,
making easier the oxidation process.3.5. In vitro cytotoxicity analysis and IC50 determination
Colorectal cancer (CRC) derived cell lines RKO and SW480, asFig. 8. Ru2 interfere with cell cycle in RKO colorectal cancer cell lines. (A) Analysis of th
and 2  IC50, in RKO and SW480 cell lines. Values represent mean ± S.D. of at least three ind
compared with negative control. (B) Representative histograms of PI staining in RKO and Swell as NCM460, a noncancerous cell line derived from normal
colon epithelial cells, were incubated for 48 h with different con-
centrations of Ru1 and Ru2 compounds to assess cell growth by
Sulphorhodamine B (SRB) assay. Compound L1 could not be tested
since its solubility in cellular media (and DMSO) is very limited. Ru1
compound had no signiﬁcant effect at the concentrations tested
compared to the negative controls in the three cell lines (Fig. S3).
Ru2 proved to be a very active compound in colorectal cancer cell
lines showing a signiﬁcant decrease in cell growth even for low
doses and not exhibiting a signiﬁcant effect on the noncancerous
cell line NCM460 that showed to be more resistant (Fig. 6). Ru2
compound affects the growth of these cells in values in the
micromolar range. The half-maximal inhibitory concentratione distribution of cell-cycle phases by ﬂow cytometry, after 48 h of incubation with IC50
ependent experiments. Statistical analysis was performed by multiple t-tests. *P ¼ 0.05
W480 were performed using FlowJo 7.6 software.
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the mean values of SRB for all lines analyzed using GraphPad Prism
6 software. The IC50 values for RKO and SW480, were 2 mM and
1.5 mM, respectively, being 4e6 times better than the positive
control cisplatin, and for NCM460 cells the IC50 was 8.7 mM (Table 4,
Fig. S4).
The results showed that for Ru2 the colorectal cancer cellS, RKO
and SW480, are more sensitive than NCM460 cells showing a lower
IC50 than for the normal colon cells. The IC50 values obtained in the
SW480 cell line are in the same range of those obtained for other
ruthenium arene complexes with modiﬁed paullones [49] or 8-
substituted indolo[3,2-c]quinolines [50] (IC50 ¼ 0.64e4.1 or
0.13e5.0 mM at 96 h incubation, respectively) and are much better
than indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
[51] (KP1019; 43 ± 8 at 96 h incubation).3.6. Proliferation and apoptosis analysis
In order to evaluate the clonogenic ability of Ru2 in RKO and
SW480 a colony formation assay was performed using the ¼ IC50Fig. 9. Ru2 increases levels of TUNEL positive cells in colorectal cancer cell lines. RKO an
concentrations for 48 h. (A) Analysis of TUNEL assay in RKO and SW480 cells. Values repr
performed by one-way ANOVA with Turkey's multiple comparisons test. *P ¼ 0.05; **P ¼ 0
images (200) of TUNEL assay. DAPI (40 ,6-diamidino-2-phenylindole), FITC (ﬂuorescein isoand IC50 values. In both cell lines the Ru2 compound affected the
ability to form colonies in a dose-dependent manner (Fig. 7). Ru2,
at a concentration of 2 mM (IC50), inhibits the ability to produce
colonies in the RKO cell line.
The cell cycle distribution was assessed by ﬂow cytometry, after
48 h of exposure to the IC50 and 2 IC50 values for RKO and SW480.
Two peaks corresponding to the G0/G1 and G2/M phases of the cell
cycle were evident in DNA content histograms (Fig. 8). Comparing
with the negative control, the IC50 value does not affect the cell
cycle phases, in the RKO cell line. However, the 2 IC50 value led to
an increase in the percentage of cells in G0/G1 cell cycle phase and,
consequently, an arrest at that phase. Relatively to the hypodiploid
sub-G1 cell-cycle phase, only for RKO, the 2 IC50 value showed an
increase in the percentage of cells (5%) comparing with the nega-
tive control (1.5%). SW480 did not show signiﬁcant differences
between treatments compared to the negative control.
We also assessed the levels of late apoptosis by TUNEL assay,
after an incubation for 48 h with IC50 and 2  IC50 values for both
cell lines. In comparison to the negative control, there were sig-
niﬁcant increase in the number of TUNEL positive cells with 2 mMd SW480 cells were analyzed by TUNEL assay, after incubation with IC50 and 2  IC50
esent mean ± S.D. of at least three independent experiments. Statistical analysis was
.01; ***P ¼ 0.001; ****P ¼ 0.0001 compared with negative control. (B) Representative
thiocyanate) and merged were obtained by ﬂuorescence microscopy.
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vs. 3% and 5%) for SW480 (Fig. 9). In both cell lines apoptotic bodies
were observed, phenotypic alterations typical of apoptosis.
Our results suggest that Ru2 seems to have more effect in RKO
than in SW480 cells, which could be related with the different
genetic background of the cells.
4. Conclusions
A new bipyridine-perﬂuorinared ligand L1 and two ruthenium
organometallic complexes, Ru1 and Ru2, were newly synthesized
and characterized. L1 and Ru1 were also studied by single-crystal
X-ray. Both compounds crystalize in the centrosymmetric triclinic
space group P1. Ru1 and Ru2 cytotoxicity was evaluated in two
human derived CRC cell lines, RKO and SW480, and in a noncan-
cerous cell line, NCM460. While compound Ru1 was not cytotoxic
for any of the tested cell lines, compound Ru2, [Ru(h5-
MeCp)(PPh3)(L1)][CF3SO3], inhibit cell growth of the two human
colon cell lines tested at low IC50 doses (2 and 1.5 mM) in compar-
ison with the normal colon derived cells NCM480 (IC50 ¼ 8.7 mM).
Moreover, Ru2 could inhibit colony formation and induce apoptosis
in CRC cell lines. Our results suggest that Ru2 show an intrinsic
selectivity towards cancer cells in relation to the normal colon
epithelial derived cells which is approximately 4 times more
resistant to the Ru2 compound.
Overall, our results indicate that Ru2 seems a very promising
candidate for future studies aiming at understanding its mecha-
nism of action in order to investigate its potential use as a new
anticancer agent to be used at least in colorectal cancer therapy
strategies.
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